We have utilized our TTP Translational Technology® in the discovery of preclinical and clinical drug candidates against multiple molecular target classes such as kinases, GPCRs, phosphatases, proteases, and protein-protein interactions. Our programs are directed at the therapeutic areas where there are significant unmet medical needs such as CNS diseases, metabolic diseases, cardiovascular diseases, inflammatory diseases and cancer.

TTP Translational Technology® has been employed to discover unique molecules as therapies for various diseases such as oral GLP1r agonist for diabetes, oral BACE1 inhibitors for Alzheimer's disease and liver selective glucokinase activators for diabetes.